Payment overview · 2025
General Payments
$474.65
19 reported records · 10 companies
Healthcare provider profile · identity verified
Robert Raymond Daiber, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MAUMEE, OH · NPI 1922147818
Verified facts
What the public records show
CMS Open Payments records show Robert Raymond Daiber, M.D. received $474.65 in general payments during 2025 across 19 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 27.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Rexulti, Vivitrol, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIVITROL as an associated drug or biological on 9533 records involving 5661 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vivitrol by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Caplyta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $130.89 | 27.6% | 2 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $85.42 | 18.0% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $53.05 | 11.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $52.74 | 11.1% | 3 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $44.10 | 9.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $33.71 | 7.1% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $29.21 | 6.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.41 | 3.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.55 | 3.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.57 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $363.16 | 18 |
| Education | $111.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $85.42 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $53.05 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $52.74 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $51.12 | 3 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $29.21 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $26.76 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $19.40 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VIVITROL vivitrol |
2025 | Vivitrol | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | VIVITROL open payments reported associated product |
CMS Open Payments — General Payments 9533 supporting records · 5661 recipient NPIs · example record 1222428584 |
Vivitrol · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
150 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2041 | 351 |
| Furosemide | Furosemide | 1472 | 255 |
| Eliquis | Apixaban | 1470 | 177 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1361 | 194 |
| Gabapentin | Gabapentin | 1088 | 196 |
| Sertraline Hcl | Sertraline Hcl | 969 | 163 |
| Amlodipine Besylate | Amlodipine Besylate | 958 | 184 |
| Trazodone Hcl | Trazodone Hcl | 898 | 163 |
| Pantoprazole Sodium | Pantoprazole Sodium | 814 | 166 |
| Buspirone Hcl | Buspirone Hcl | 812 | 140 |
| Potassium Chloride | Potassium Chloride | 794 | 152 |
| Divalproex Sodium | Divalproex Sodium | 757 | 115 |
| Donepezil Hcl | Donepezil Hcl | 748 | 123 |
| Lisinopril | Lisinopril | 714 | 133 |
| Tamsulosin Hcl | Tamsulosin Hcl | 712 | 142 |
| Metoprolol Tartrate | Metoprolol Tartrate | 704 | 163 |
| Lorazepam | Lorazepam | 621 | 143 |
| Quetiapine Fumarate | Quetiapine Fumarate | 605 | 102 |
| Carvedilol | Carvedilol | 587 | 116 |
| Metformin Hcl | Metformin Hcl | 567 | 98 |
| Omeprazole | Omeprazole | 548 | 123 |
| Mirtazapine | Mirtazapine | 516 | 111 |
| Metoprolol Succinate | Metoprolol Succinate | 489 | 104 |
| Losartan Potassium | Losartan Potassium | 485 | 87 |
| Memantine Hcl | Memantine Hcl | 475 | 73 |
| Tramadol Hcl | Tramadol Hcl | 471 | 89 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 470 | 90 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 462 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 431 | 76 |
| Levetiracetam | Levetiracetam | 420 | 66 |
| Famotidine | Famotidine | 400 | 96 |
| Spironolactone | Spironolactone | 375 | 78 |
| Duloxetine Hcl | Duloxetine Hcl | 370 | 61 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 364 | 78 |
| Clopidogrel | Clopidogrel Bisulfate | 363 | 83 |
| Citalopram Hbr | Citalopram Hydrobromide | 337 | 50 |
| Januvia | Sitagliptin Phosphate | 321 | 27 |
| Warfarin Sodium | Warfarin Sodium | 301 | 30 |
| Allopurinol | Allopurinol | 300 | 57 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 288 | 25 |
| Jardiance | Empagliflozin | 284 | 32 |
| Ropinirole Hcl | Ropinirole Hcl | 276 | 52 |
| Ondansetron Hcl | Ondansetron Hcl | 272 | 156 |
| Lactulose | Lactulose | 262 | 26 |
| Cephalexin | Cephalexin | 260 | 133 |
| Aripiprazole | Aripiprazole | 256 | 35 |
| Midodrine Hcl | Midodrine Hcl | 255 | 80 |
| Risperidone | Risperidone | 255 | 48 |
| Xarelto | Rivaroxaban | 253 | 40 |
| Fluoxetine Hcl | Fluoxetine Hcl | 239 | 48 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 231 | 66 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 222 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 214 | 45 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 210 | 46 |
| Simvastatin | Simvastatin | 210 | 42 |
| Bumetanide | Bumetanide | 209 | 59 |
| Clozapine | Clozapine | 207 | 11 |
| Olanzapine | Olanzapine | 206 | 48 |
| Meloxicam | Meloxicam | 203 | 33 |
| Prednisone | Prednisone | 200 | 65 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 197 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 189 | 41 |
| Oxycodone Hcl | Oxycodone Hcl | 187 | 58 |
| Alprazolam | Alprazolam | 183 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 181 | 49 |
| Baclofen | Baclofen | 175 | 33 |
| Ibuprofen | Ibuprofen | 175 | 54 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 174 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 172 | 97 |
| Fluticasone Propionate | Fluticasone Propionate | 169 | 73 |
| Benztropine Mesylate | Benztropine Mesylate | 165 | 22 |
| Bupropion Xl | Bupropion Hcl | 163 | 28 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 162 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 162 | 95 |
| Lamotrigine | Lamotrigine | 160 | 20 |
| Latanoprost | Latanoprost | 159 | 39 |
| Clonazepam | Clonazepam | 156 | 26 |
| Glimepiride | Glimepiride | 152 | 30 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 151 | 52 |
| Doxycycline Hyclate | Doxycycline Hyclate | 150 | 75 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 150 | suppressed |
| Nystatin | Nystatin | 149 | 72 |
| Lacosamide | Lacosamide | 148 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 146 | 41 |
| Trulicity | Dulaglutide | 142 | 15 |
| Levofloxacin | Levofloxacin | 139 | 78 |
| Hydralazine Hcl | Hydralazine Hcl | 138 | 38 |
| Amiodarone Hcl | Amiodarone Hcl | 135 | 31 |
| Pregabalin | Pregabalin | 133 | 31 |
| Divalproex Sodium Er | Divalproex Sodium | 132 | 26 |
| Finasteride | Finasteride | 132 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 130 | 24 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 128 | 41 |
| Albuterol Sulfate | Albuterol Sulfate | 127 | 50 |
| Farxiga | Dapagliflozin Propanediol | 126 | 19 |
| Paliperidone Er | Paliperidone | 122 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 119 | 43 |
| Rivastigmine | Rivastigmine | 115 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 114 | 66 |
| Alendronate Sodium | Alendronate Sodium | 107 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 107 | 31 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 106 | 64 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 105 | 34 |
| Montelukast Sodium | Montelukast Sodium | 103 | 23 |
| Topiramate | Topiramate | 101 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 100 | 32 |
| Entresto | Sacubitril/Valsartan | 99 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 99 | 18 |
| Myrbetriq | Mirabegron | 97 | 13 |
| Meclizine Hcl | Meclizine Hcl | 94 | 17 |
| Metformin Hcl Er | Metformin Hcl | 93 | 23 |
| Glipizide | Glipizide | 89 | 16 |
| Hydrocortisone | Hydrocortisone | 89 | 24 |
| Incruse Ellipta | Umeclidinium Bromide | 88 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 86 | 17 |
| Nitroglycerin | Nitroglycerin | 83 | 51 |
| Admelog Solostar | Insulin Lispro | 81 | 13 |
| Ezetimibe | Ezetimibe | 81 | 18 |
| Primidone | Primidone | 81 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 79 | 13 |
| Nystop | Nystatin | 79 | 37 |
| Atenolol | Atenolol | 73 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 69 | 15 |
| Morphine Sulfate Er | Morphine Sulfate | 69 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 68 | 17 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 68 | 36 |
| Lithium Carbonate | Lithium Carbonate | 68 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 67 | 15 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 67 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 19 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 66 | 21 |
| Memantine Hcl Er | Memantine Hcl | 66 | suppressed |
| Fluconazole | Fluconazole | 64 | 41 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 63 | 33 |
| Rivastigmine | Rivastigmine Tartrate | 63 | 13 |
| Haloperidol | Haloperidol | 62 | 14 |
| Novolog Flexpen | Insulin Aspart | 62 | 31 |
| Digoxin | Digoxin | 61 | 12 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 60 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 60 | 23 |
| Insulin Aspart Flexpen | Insulin Aspart | 58 | 27 |
| Clonidine Hcl | Clonidine Hcl | 56 | 22 |
| Procrit | Epoetin Alfa | 56 | suppressed |
| Amoxicillin | Amoxicillin | 55 | 37 |
| Fentanyl | Fentanyl | 54 | 13 |
| Oxcarbazepine | Oxcarbazepine | 54 | suppressed |
| Torsemide | Torsemide | 54 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 52 | 15 |
| Enulose | Lactulose | 52 | suppressed |
| Lidocaine | Lidocaine | 52 | 16 |
| Methocarbamol | Methocarbamol | 52 | 15 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 52 | suppressed |
| Rexulti | Brexpiprazole | 52 | suppressed |
| Carbamazepine | Carbamazepine | 50 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 50 | 15 |
| Brilinta | Ticagrelor | 49 | suppressed |
| Nifedipine Er | Nifedipine | 49 | 14 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 47 | suppressed |
| Methotrexate | Methotrexate Sodium | 47 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 47 | 11 |
| Sucralfate | Sucralfate | 47 | 12 |
| Azithromycin | Azithromycin | 46 | 30 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 46 | 11 |
| Ziprasidone Hcl | Ziprasidone Hcl | 45 | suppressed |
| Carbamazepine Er | Carbamazepine | 44 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 44 | 23 |
| Ketoconazole | Ketoconazole | 44 | 21 |
| Meropenem | Meropenem | 44 | 11 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 43 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 31 |
| Metronidazole | Metronidazole | 43 | 20 |
| Novolog | Insulin Aspart | 43 | 20 |
| Propranolol Hcl | Propranolol Hcl | 43 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 11 |
| Lovastatin | Lovastatin | 42 | suppressed |
| Metolazone | Metolazone | 42 | 13 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 41 | 40 |
| Vascepa | Icosapent Ethyl | 41 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 12 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 40 | suppressed |
| Nyamyc | Nystatin | 40 | 26 |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 40 | suppressed |
| Sulfasalazine | Sulfasalazine | 40 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 39 | 11 |
| Budesonide | Budesonide | 39 | 11 |
| Celecoxib | Celecoxib | 39 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 39 | suppressed |
| Linzess | Linaclotide | 39 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 38 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 38 | suppressed |
| Insulin Lispro | Insulin Lispro | 38 | 22 |
| Invega Sustenna | Paliperidone Palmitate | 38 | suppressed |
| Calcium Acetate | Calcium Acetate | 37 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 37 | 32 |
| Neupro | Rotigotine | 37 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 37 | 14 |
| Tobramycin | Tobramycin | 37 | 31 |
| Cilostazol | Cilostazol | 35 | suppressed |
| Glucagon Emergency Kit | Glucagon | 35 | 18 |
| Humalog | Insulin Lispro | 35 | 16 |
| Methadone Hcl | Methadone Hcl | 35 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 34 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 34 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 33 | 11 |
| Lurasidone Hcl | Lurasidone Hcl | 33 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 33 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 33 | 13 |
| Amantadine | Amantadine Hcl | 32 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 32 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 32 | suppressed |
| Tradjenta | Linagliptin | 32 | suppressed |
| Colchicine | Colchicine | 31 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 31 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 31 | suppressed |
| Daptomycin | Daptomycin | 30 | suppressed |
| Gemtesa | Vibegron | 30 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 21 |
| Roflumilast | Roflumilast | 30 | suppressed |
| Scopolamine | Scopolamine | 30 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 29 | suppressed |
| Gemfibrozil | Gemfibrozil | 29 | suppressed |
| Ozempic | Semaglutide | 29 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 28 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 28 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 28 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 28 | 16 |
| Insulin Aspart | Insulin Aspart | 28 | 13 |
| Levemir | Insulin Detemir | 28 | suppressed |
| Loperamide | Loperamide Hcl | 28 | 23 |
| Nuplazid | Pimavanserin Tartrate | 28 | suppressed |
| Oxycontin | Oxycodone Hcl | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Zonisamide | Zonisamide | 28 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 27 | 12 |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Calcitriol | Calcitriol | 27 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 27 | 17 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 27 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 27 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 27 | suppressed |
| Xifaxan | Rifaximin | 27 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 26 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 19 |
| Aptiom | Eslicarbazepine Acetate | 25 | suppressed |
| Caplyta | Lumateperone Tosylate | 25 | suppressed |
| Cefdinir | Cefdinir | 25 | 15 |
| Diltiazem Hcl | Diltiazem Hcl | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 25 | suppressed |
| Briviact | Brivaracetam | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | 17 |
| Cholestyramine Light | Cholestyramine | 23 | suppressed |
| Cimetidine | Cimetidine | 23 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 23 | 21 |
| Alogliptin | Alogliptin Benzoate | 22 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 22 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 22 | 11 |
| Ingrezza | Valbenazine Tosylate | 22 | suppressed |
| Rytary | Carbidopa/Levodopa | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 21 | 17 |
| Liothyronine Sodium | Liothyronine Sodium | 21 | suppressed |
| Phenytoin | Phenytoin | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 20 | suppressed |
| Dexamethasone | Dexamethasone | 20 | 14 |
| Ertapenem | Ertapenem Sodium | 20 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 20 | suppressed |
| Matzim La | Diltiazem Hcl | 19 | suppressed |
| Ramelteon | Ramelteon | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 18 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 12 |
| Clonidine | Clonidine | 17 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 17 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 17 | suppressed |
| Klayesta | Nystatin | 17 | 11 |
| Levalbuterol Hcl | Levalbuterol Hcl | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Trospium Chloride | Trospium Chloride | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 16 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 16 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 16 | suppressed |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 15 | suppressed |
| Letrozole | Letrozole | 15 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 15 | suppressed |
| Trifluoperazine Hcl | Trifluoperazine Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Abilify Maintena | Aripiprazole | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Levocarnitine | Levocarnitine | 14 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 14 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Np Thyroid | Thyroid,pork | 14 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 14 | suppressed |
| Cyclosporine | Cyclosporine | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 12 | suppressed |
| Insulin Glargine Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 12 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 12 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 12 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 11 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Fycompa | Perampanel | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 11 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 11 | suppressed |
| Vivitrol | Naltrexone Microspheres | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $474.65 · 19 records | Teva Pharmaceuticals USA, Inc. | ARISTADA, AUSTEDO XR, BRIXADI, CAPLYTA, EVENITY, FANAPT, LYBALVI, REXULTI, SUBLOCADE, VIVITROL, VRAYLAR | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error